New Delhi: The World Health Organization on Monday cleared its stance on considering the inclusion of Bharat Biotech’s Covaxin for an emergency-use listing (EUL) for vaccination against coronavirus disease, saying that WHO cannot “cut corners” in making a decision.
WHO is further expecting one additional piece of information from Covaxin manufacturer, Bharat Biotech to consider the company’s request for allowing the inclusion of the vaccine in the emergency-use listing for vaccination.
As per the reports, the Hyderabad-based company which developed India’s first indigenous COVID-19 vaccine started sharing data with WHO from early July this year. While, the vaccine was given emergency-use authorisation in India in January.
“The timeframe for the WHO Emergency Use Listing procedure is dependent on how quickly a company producing the vaccine is able to provide the data required for WHO to evaluate the vaccine’s quality, safety, efficacy and its suitability for low- and middle-income countries,” the WHO posted on Twitter.
Apart from this, WHO chief scientist Soumya Swaminathan has also said that the technical advisory group of the UN health Agency will meet on October 26 to decide on the emergency use listing of Covaxin.
Why is emergency-use authorisation important?
It is important to note that WHO’s nod for Covaxin’s emergency use authorisation is necessary because without WHO’s approval, Covaxin is unlikely to be accepted as safe and effective vaccine around the world.
Also, without WHO’s nod, this Indian-made vaccine would complicate travel plans for millions of Indians who have been vaccinated with both of its doses.